Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
CAS RN: 150322-43-3 | Product Number: P2040
Prasugrel
Purity: >98.0%(T)(HPLC)
- 5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl Acetate
Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
---|---|---|---|---|---|
200MG |
$131.00
|
6 | 1 | 14 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
Product Number | P2040 |
Purity / Analysis Method | >98.0%(T)(HPLC) |
Molecular Formula / Molecular Weight | C__2__0H__2__0FNO__3S = 373.44 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Refrigerated (0-10°C) |
Condition to Avoid | Heat Sensitive |
CAS RN | 150322-43-3 |
Reaxys Registry Number | 9008623 |
PubChem Substance ID | 172089108 |
MDL Number | MFCD09954140 |
Appearance | Light yellow to Yellow to Orange powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Purity(Nonaqueous Titration) | min. 98.0 % |
Melting point | 120.0 to 124.0 °C |
NMR | confirm to structure |
Melting Point | 122 °C |
HS Number | 2930.90.2900 |
References
- Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
- Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
- Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
- Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity
- The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite
Articles/Brochures
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.